In its latest quarterly update, Adagio Medical Holdings reported no revenue for Q1 2026 reflecting a continued strategic pause in commercial activity while completing enrollment in its pivotal FULCRUM-VT trial. The company’s proprietary Ultra-Low Temperature Ablation (ULTA) technology targets the underserved ventricular tachycardia (VT) market with promising clinical data under FDA Breakthrough Device Designation. However, despite critical regulatory progress, Adagio faces substantial liquidity constraints with less than a year’s runway at current burn levels. Its growth hinges on forthcoming clinical trial results and securing additional funding to enable FDA approval and commercial launch in the U.S.